News & Press releases
Vimian Group AB (“Vimian”) has successfully issued new senior unsecured bonds (the “Bonds” and the “Bond Issue”, respectively) of EUR 150 million with a tenor of three years, within a framework of EUR 250 million. The Bonds will carry a floating interest of EURIBOR 3m plus 200 basis points per annum.
Vimian Group AB (publ) (“Vimian”), Reg. No. 559234-8923, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on 11 June 2025 at 11.00 CEST in Advokatfirman Vinge’s premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 10.30 CEST.
Vimian Group AB (public) (“Vimian”) has today mandated DNB Markets, a part of DNB Bank ASA, Sweden Branch, Nordea Bank Abp and Skandinaviska Enskilda Banken AB (publ) as joint bookrunners to arrange a series of fixed income investor meetings starting on 9 May 2024 to explore the possibility of issuing a senior unsecured bond denominated in EUR with floating-rate interest and expected maturity in 3 years. A capital markets transaction with an expected volume of EUR 125 million within a framework of EUR 250 million may follow, subject to prevailing market conditions.
Vimian held its Annual General Meeting today 29 April 2025. The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The Annual General Meeting in Vimian Group AB (publ) resolved the following:
Vimian's MedTech segment is supported by its Scientific Advisory Board (SAB), consisting of some of the most well-renowned veterinary surgeons worldwide. We spoke with Terri Schiller, a board-certified small animal veterinary surgeon, about her role on the Scientific Advisory Board and its significance.
Vimian Group AB (publ) (“Vimian”), Reg. No. 559234-8923, with its registered office in Stockholm, gives notice of the Annual General Meeting to be held on 29 April 2025 at 15.00 CEST at Norrlandsgatan 10, SE-111 43 Stockholm, Sweden. Registration starts at 14.30 CEST.
Vimian Group AB (publ) (”Vimian” or the ”Company”) announced on 14 March 2025 that Nasdaq Stockholm’s listing committee had approved Vimian’s application to admit the Company’s ordinary shares to trading on Nasdaq Stockholm’s Main Market. The prospectus that has been prepared in connection with the uplisting has today been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”) and is now available on Vimian’s website, www.vimian.com, and on the SFSA’s website, www.fi.se.
The Nomination Committee in Vimian Group AB (publ) proposes that Pia Marions is appointed new Board member at the Annual General Meeting in April 2025. Furthermore, the Nomination Committee has been informed that Robert Belkic and Frida Westerberg have declined re-election.
Nasdaq Stockholm’s Listing Committee has today approved Vimian Group AB (publ)’s (“Vimian” or the “Company”) application for admission of Vimian’s ordinary shares to trading on Nasdaq Stockholm. The approval is subject to customary conditions, including the approval and registration of a prospectus with the Swedish Financial Supervisory Authority. The first day of trading on Nasdaq Stockholm is expected to be Friday, 28 March 2025 and the last day of trading on Nasdaq First North Growth Market is expected to be Thursday, 27 March 2025.
Vimian’s orthopedics business is at the forefront of veterinary knee surgery, offering a comprehensive suite of solutions to address cranial cruciate ligament injuries, when bands inside the knee get hurt or torn, in dogs. These injuries, similar to ACL tears in humans, are among the most common orthopaedic issues in canines. Vimian’s innovative approach ensures that veterinarians have access to advanced techniques and implants tailored to every dog's need.
At Vimian, we partner with visionary entrepreneurs who drive innovation in animal health. We sat down with Nick Bova, founder of Bova, to discuss his journey from running a family-owned retail pharmacy to becoming an integral part of Vimian's Specialty Pharma segment (Nextmune). Learn how his passion for veterinary medicine led to the creation of a business that has transformed veterinary care across Australia, UK and beyond.
Creating the best place to work for its people is a core value driver for Vimian. Leadership development forms an integral part of this agenda and Vimian is focused on creating an infrastructure that attracts, retains, and nurtures talent across the organisation.
Vimian partners with successful entrepreneurs in animal health to make the market’s most innovative products and services available to more professionals and pet owners. We sat down with one of these founding entrepreneurs, John Wagoner, who founded the US based company VerticalVet that was acquired by Vimian in 2021. Learn how it was to become an integral part of Vimian’s global family.
Meet Dr. Slobodan Tepic, the founder of KYON, today one of the product brands in Vimian’s MedTech segment Movora. Learn about his journey from innovative orthopaedic solutions for pets to becoming an integral part of Vimian.
Vimian Group AB (publ) has today signed an agreement to acquire 100 per cent of iM3 Dental Limited in Ireland and 80 per cent of iM3 Pty Ltd in Australia, hereafter referred to as “iM3”, a global leading provider of veterinary dental products and equipment. iM3 had consolidated annual revenues the past twelve months ending July 2024 of around EUR 35.9 million and a consolidated EBITDA of around EUR 7.7 million. The purchase price amounts to EUR 84 million subject to customary net debt and working capital adjustments, partly financed through an issue in kind of 735,353 ordinary shares and 735,353 C-shares at a total value of approximately EUR 5 million as a reinvestment in Vimian [1]. An additional possible amount of maximum EUR 60 million may be vested over a five-year period, subject to ambitious EBITDA hurdles.
Vimian Group AB (publ) has been informed that the Company’s largest shareholder Fidelio Vet Holding AB (“Fidelio”) has undertaken to issue 100,000 call options in Vimian to Magnus Welander, Chairman of the Board in Vimian Group AB (publ).
The number of shares and votes in Vimian Group AB (publ) (“Vimian”) has changed as a result of conversion of in total 7,446,367 C-shares into ordinary shares carried out in June following requests from shareholders in accordance with the conversion clause in Vimian’s articles of association.
Vimian Group AB (publ)’s subsidiaries, part of Vimian’s MedTech segment, have reached a settlement agreement with one of the main sellers of Veterinary Orthopedic Implants, LLC (“VOI”). The seller has agreed to compensate Vimian for his entire pro rata share, amounting to 37 per cent, of the USD 70 million settlement payment to DePuy Synthes. The total value of the settlement amounts to approximately USD 26 million.
Vimian held its Annual General Meeting today 22 May 2024. The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The Annual General Meeting in Vimian Group AB (publ) resolved the following:
Vimian Group AB (publ) (“Vimian”), Reg. No. 559234-8923, with its registered office in Stockholm, gives notice of the Annual General Meeting to be held on 22 May 2024 at 10.00 a.m. CEST at Advokatfirman Vinge’s premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 9.30 a.m. CEST.
The Board of Directors of Vimian AB (publ) has today adopted new financial targets. Since the previous financial targets were set three years ago, Vimian has more than doubled its revenues and adjusted EBITA through strong organic growth and 32 value-creative acquisitions that have strengthened the Company’s market positions in attractive niches of the animal health market and changed the composition and profile of the Company.
The Nomination Committee in Vimian Group proposes that Magnus Welander is appointed new Chairman of the Board of Directors at the Annual General Meeting in May 2024, and that the current Chairman Gabriel Fitzgerald is elected ordinary Board member.
Vimian Group AB (publ)’s subsidiaries, part of Vimian’s MedTech segment, have reached a settlement agreement with Dr. Brian Beale, one of the four sellers of Veterinary Orthopedic Implants, LLC (“VOI”). Dr. Beale has agreed to compensate Vimian for his entire pro rata share, which amounts to five per cent, of the USD 70 million settlement payment to DePuy Synthes, corresponding to a total value of USD 3.5 million.
Vimian Group AB (publ) (“Vimian”) appoints Patrik Eriksson Chief Executive Officer, effective 1 January 2024. Patrik Eriksson joins Vimian from Envista, a global dental company listed on NYSE, where he currently serves on the Executive Team as President of Nobel Biocare.
Colleen Flesher has decided to step down from the Vimian Group management team and the position as Co-CEO Movora, to pursue an opportunity outside Vimian in another industry. Guy Spörri, today Co-CEO Movora, will assume full responsibility for the business from 1 December 2023.
The number of votes in Vimian Group AB (publ) (“Vimian”) has changed as a result of (i) redemption of 5,320 C-shares, and (ii) conversion of in total 6,296,610 C-shares into ordinary shares carried out in September following requests from shareholders in accordance with the conversion clause in Vimian’s articles of association.
Today, Vimian Group AB (publ) (“Vimian”) announces that CEO Fredrik Ullman, following consultation with the Board, steps down as CEO. Fredrik Ullman has been the CEO of Vimian since its inception in 2020 and the CEO of its subsidiary Indical Bioscience since 2018. The recruitment process for a new CEO will be initiated immediately with Fredrik Ullman remaining as CEO in the interim and at the latest until year-end.
Vimian held its Annual General Meeting today 2 June 2023. The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The Annual General Meeting in Vimian Group AB (publ) resolved the following:
Vimian har idag den 2 juni 2023 hållit årsstämma. Årsstämman genomfördes med fysisk närvaro av aktieägare och med möjlighet för aktieägare att utöva sin rösträtt genom förhandsröstning (poströstning). Årsstämman i Vimian Group AB (publ) fattade följande beslut:
Following the settlement in the US patent dispute on 4 April, Vimian has initiated the process to retrieve compensation from the Sellers of Vimian’s subsidiary Veterinary Orthopedic Implants LLC (“VOI”) as per the indemnification in the purchase agreement from the acquisition of VOI. Vimian has received information that a complaint was filed against Vimian and three affiliates of Vimian in the Superior Court of the State of Delaware. Three of the main Sellers state in the complaint that they disagree with Vimian’s indemnification claim.
Vimian Group AB (publ) (“Vimian”), Reg. No. 559234-8923, with its registered office in Stockholm, gives notice of the Annual General Meeting to be held on 2 June 2023 at 9 a.m. CEST at Advokatfirman Vinge’s premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 8.30 a.m. CEST.
Vimian Group today announces that the board of directors, based on the authorization from the 2022 annual general meeting, has resolved on a share issue of 249,482 ordinary shares and 249,482 class C shares as part of an earn-out payment to the sellers of Kahu Vet Group in accordance with the share purchase agreement signed in February 2022.
Vimian Group AB (publ)’s (“Vimian”) subsidiary, Veterinary Orthopedic Implants, LLC (“VOI”), part of Vimian’s MedTech segment and Fidelio, have reached a settlement agreement with DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. (“Synthes”), resolving the patent dispute between the parties. Under the terms of the agreement, the defendants are obliged to make a single payment of USD 70 million. Vimian’s view is that through the purchase agreement for the acquisition of VOI, Vimian has contractual indemnification protection for the amount of the settlement and all legal costs to date.
Vimian Group AB (publ) (”Vimian”), org.nr 559234-8923, med säte i Stockholm, kallar till extra bolagsstämma den 24 mars 2023 kl. 15:00 i Advokatfirman Vinges lokaler på Smålandsgatan 20, 111 46 Stockholm. Inregistrering till stämman börjar kl. 14:30.
Vimian Group AB (publ) (“Vimian”), Reg. No. 559234-8923, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on 24 March 2023 at 15:00 CET at Advokatfirman Vinge’s premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 14:30 CET.
Vimian has amended the share purchase agreement for the acquisition of Viking Blues Pty Ltd (the non-regulated part of Bova Australia) that was announced in Vimian’s Q2 report, agreeing that 84 per cent of the upfront consideration shall be paid by an issue in kind of ordinary shares in Vimian, subject to approval by an extraordinary general meeting.
A jury in the U.S. Middle District of Florida decided today that Vimian Group AB (publ)’s (“Vimian”) subsidiary, Veterinary Orthopedic Implants, LLC (“VOI”), which is part of Vimian’s MedTech segment, infringes certain patent rights of DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. (“Synthes”). The jury awarded Synthes USD 59.5 million in damages and found wilful infringement by VOI. Through the purchase agreement for the acquisition of VOI, Vimian has contractual indemnification protection for the amount of the verdict.
The number of votes in Vimian Group AB (publ) (“Vimian”) has changed as a result of conversions of in total 6,019,086 C-shares into ordinary shares carried out in January following requests from shareholders in accordance with the conversion clause in Vimian’s articles of association.
Colleen Flesher, currently COO Movora, has been appointed new Co-CEO of Movora, the operating company within Vimian’s MedTech segment. Colleen assumes her position on 1 December and succeeds Patrick Gendreau and Christopher Sidebotham who have decided to step down.
Vimian held its Extraordinary General Meeting today 3 October 2022. The Extraordinary General Meeting was conducted by postal voting only, without physical presence of shareholders, proxies and third parties, pursuant to temporary legislation.
Vimian Group has acquired Heiland GmbH (“heiland.com”), a leading online ordering platform offering veterinary pharmaceuticals and other veterinary products to veterinary clinics across Germany. The acquisition marks a key milestone in Vimian Group’s strategy to digitalise its global service offering for veterinary clinics. Heiland.com has annual revenues of around EUR 1.5 million.
Vimian Group appoints Carl-Johan Zetterberg Boudrie as new Chief Financial Officer (CFO) and intends to continue to build out its finance organisation to support Vimian’s growth journey. Carl-Johan assumes the position as CFO and member of the Vimian Group management team, and succeeds Henrik Halvorsen who has decided to focus on his role as CFO of Vimian’s Specialty Pharma segment Nextmune.
Vimian held its Annual General Meeting today 2 June 2022. The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The Annual General Meeting in Vimian Group AB (publ) resolved the following:
Vimian har idag den 2 juni 2022 hållit årsstämma. Årsstämman genomfördes med fysisk närvaro av aktieägare och med möjlighet för aktieägare att utöva sin rösträtt genom förhandsröstning (poströstning). Årsstämman i Vimian Group AB (publ) fattade följande beslut:
Vimian Group AB (publ) (“Vimian”), Reg. No. 559234-8923, with its registered office in Stockholm, gives notice of the Annual General Meeting to be held on 2 June 2022 at 10.00 CEST at Advokatfirman Vinge’s premises at Smålandsgatan 20, SE-111 87 Stockholm, Sweden.
Vimian Group has acquired two product portfolios of veterinary surgical instruments and orthopedic implants in the US. The acquisition marks the entry into a new product category with veterinary surgical instrumentation and expands Vimian’s portfolio of high-quality orthopedic implants for companion animals. The acquired portfolios have combined annual revenues of around USD 6.5 million.
Vimian Group has acquired Vertical Vet, LLC (VerticalVet), one of the leading providers of procurement and support services to more than 1,100 member clinics in the United States (US). The acquisition marks the entrance into a new geography for Vimian’s Veterinary Services segment, VetFamily, and significantly strengthens its position as a leading veterinary services platform globally. VerticalVet is fast-growing and generated revenues of around USD 6 million in 2021.
Vimian Group has acquired Vet-Allergy, a veterinary allergy company in Denmark, to strengthen its position as a leading provider of veterinary allergy diagnostics and treatment in Scandinavia. Vet-Allergy has revenues of around EUR 1.3 million on an annual basis.
Vimian Group has today signed an agreement to acquire Kahu Vet Group (“Kahuvet”), a supplier of veterinary surgical products in New Zealand and Australia. The acquisition represents a milestone in Vimian’s strategy to expand its geographical presence and establish direct sales in selected key and underpenetrated markets. Kahuvet is a fast-growing company with revenues of around EUR 8.5 million in 2021.
Vimian Group has today signed an agreement to acquire Bova Holdings Limited (Bova), a leading companion animal health specialty pharmaceuticals company in the United Kingdom (UK). The company offers customised specialty pharmaceuticals for companion animals and had annual revenues the past twelve months of GBP 8.1 million and an EBITDA of GBP 2.9 million. On a full-year basis for Bova’s financial year 2021 ending March 2022, Bova is expected to have annual revenues of GBP 8.9 million and an EBITDA of GBP 3.6 million, corresponding to an EBITDA margin of 40 percent. The purchase price (enterprise value) amounts to GBP 50.5 million and an additional, possible amount of maximum GBP 25.5 million vested over a three-year period and subject to EBITDA hurdles.
